EFTA01461473.pdf

From: Tazia Smith Sent: 3/25/2014 9:30:03 AM To: jeevacation ail.com CC: Paul Morris Vinit Sahn Nay Gupta Subject: Biotech Sell-Off.... [I) Attachments: pic18427.gif; pic32145.gif; pic19647.gif; pic07634.gif; pic00882.gif; pic18938.gif; pic19032.gif; pic24269.gif; pic27759.gif; pic32626.gif; pic31712.gif; pic27299.gif; pic09443.gif classification: For internal use only Jeffrey - Biotech posted sharp declines. You are up $970,282 across your basket of names as of yesterday's (3/24) close (detail below along with chart of Nasdaq Biotech Index and your holdings). Consider unwinding or hedging now and watching for entry point via total return swap or zero cost risk reversal as this negative momentum bottoms out. Note: Ariad an outlier (incrementally positive news on drug, Iclusig). The Financial Times features an article this morning suggesting that the sell-off in Biotech is a signal of a broader market peak. A letter from congressional representatives to Gilead questioning its plans to sell a hepatitis C drug (named Sovaldi) for $84,000 per dose has put the spotlight on Congress' concerns that the expense might saddle state Medicaid programs with steep costs. US is the only major health-care market remaining without any meaningful drug price controls -- increased risk for the sector once the Congress gets involved, especially if focused primarily on pricing. (Embedded image moved to file: pic18427.gif) Nasdaq Biotech Index - lyr Price History (Embedded image moved to file: pic3214S.gif) Ariad - lyr Price History (Embedded image moved to file: pi c19647.gi f) Biogen - lyr Price History (Embedded image moved to file: pic07634.gif) Foundation medical - lyr Price History (Embedded image moved to file: pi c00882.gi f) Gilead - lyr Price History (Embedded image moved to file: pic18938.gif) Sangamo - lyr Price History (Embedded image moved to file: pi c19032.gi f) Healthcare sector has outperformed S&PS00 last 4 years and has been the best-performing sector YTO Improving R&O returns Ongoing efficiency gains due to various 'self-help' measures More supportive regulatory and payor environment Increasing number of financings and IPOs in Q1 • Frequent upward revisions lately to sales estimates at the largest biotechnology companies CONFIDENTIAL — PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0123545 CONFIDENTIAL SDNY_GM_00269729 EFTA01461473